drugset / Trial / NCT07234695
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
Phase 3
Recruiting
120 enrolled
Sant Pau Research Institute
Fundación CITA Alzheimer · collabFundación de Investigación Biomédica - Hospital Universitario de La Princesa · collabHospital Universitario Marqués de Valdecilla · collabUniversity Hospital Virgen de las Nieves · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate whether levetiracetam can prevent epileptic seizures in patients with Alzheimer's disease associated with Down syndrome. It will also analyze whether it can delay the neurodegeneration associated with this disease. Patients will be randomly assigned to one of two groups: one group will receive the active drug (levetiracetam), and the other will receive a placebo. Both groups will receive the treatment for 96 weeks. Each patient will participate for a total of 2 years and 5 months.
Timeline
- Start
- 2025-12-22
- Primary completion
- 2027-12
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levetiracetam | Other / unclassified | 500 mg | Oral |